PLX - .6612 Pre-market now at .72/.725 Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis http://stockcharts.com/c-sc/sc?s=PLX&p=D&b=5&g=0&i=t51237315080&r=1514898268205 http://stockcharts.com/c-sc/sc?s=PLX&p=W&b=5&g=0&i=t81012806991&r=1514898296180